Skip to main content

Table 1 Patient characteristics for the whole group of asthmatics who had a smoking history of at least 10 pack-years, and according to asthma symptom control level as per the GINA guidelines

From: Symptom control among asthmatics with a clinically significant smoking history: a cross-sectional study in Finland

 

All subjects

(n = 190)

Well controlled

(n = 66)

Partially controlled

(n = 81)

Uncontrolled

(n = 43)

P-value*

Age (years)

58.0 (50.0–65.0)

59.5 (52.0–65.0)

57.0 (49.0–65.0)

58.0 (49.0–64.0)

0.79

Females

112 (58.9)

36 (54.5)

46 (56.8)

30 (69.8)

0.25

BMI (kg/m2)

27.5 (24.2–31.1)

26.3 (24.2–30.1)

27.5 (24.3–31.2)

27.9 (23.9–33.3)

0.47

Current smokers

83 (44.1)

23 (35.4)

34 (42.0)

26 (61.9)

0.02 (0.01)***

Pack-years

20.0 (15.0–30.0)

20.0 (15.0–30.0)

20.0 (15.0–27.0)

26.0 (15.0–35.0)

0.25

FEV1 (% of predicted)

80.5 (71.0–93.0)

84.0 (71.0–94.0)

83.0 (72.0–95.0)

78.0 (67.0–83.0)

0.03 (0.03)**

Significant reversibility in FEV1

17 (8.9)

5 (7.6)

5 (6.2)

7 (16.3)

0.15

Post-bronchodilator FEV1/FVC

0.74 (0.68–0.79)

0.73 (0.68–0.77)

0.75 (0.70–0.81)

0.72 (0.68–0.80)

0.24

Post bronchodilator FEV1/FVC < 0.70

52 (27.4)

17 (25.8)

22 (27.2)

13 (30.2)

0.88

Exacerbation during previous year

51 (26.8)

7 (10.6)

27 (33.3)

17 (39.5)

0.001 (< 0.001)***

Regular use of inhaled corticosteroid

179 (94.2)

63 (95.5)

77 (95.1)

39 (90.7)

0.53

Regular use of inhaled corticosteroid +

long-acting b2-agonist (ICS + LABA)

122 (64.2)

42 (63.6)

56 (69.1)

24 (55.8)

0.34

  1. The results are given as the median (interquartile range) or number of patients (percentage)
  2. *Kruskal-Wallis test was used for continuous variables, and the chi-squared test was used for comparisons of categorical variables among groups according to asthma control
  3. **Jonckheere-Terpstra trend test in parentheses
  4. ***Mantel-Haenzel trend test in parentheses